Cargando…

Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes

OBJECTIVE: Cisplatin forms the backbone of systemic chemotherapy treatment for oropharyngeal squamous cell carcinoma (OPSCC). The ideal cisplatin dosing regimen remains yet to be fully defined for achieving optimal efficacy and toxicity profiles in patients with comorbidity. METHODS: We retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, Ola, Wilde, David C., Kemnade, Jan O., Sabichi, Anita L., Chen, George, Chen, Albert, Little, Samantha N., Huang, Andrew T., Hernandez, David J., Sandulache, Vlad C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446265/
https://www.ncbi.nlm.nih.gov/pubmed/37621289
http://dx.doi.org/10.1002/lio2.1115
_version_ 1785094368658456576
author Soliman, Ola
Wilde, David C.
Kemnade, Jan O.
Sabichi, Anita L.
Chen, George
Chen, Albert
Little, Samantha N.
Huang, Andrew T.
Hernandez, David J.
Sandulache, Vlad C.
author_facet Soliman, Ola
Wilde, David C.
Kemnade, Jan O.
Sabichi, Anita L.
Chen, George
Chen, Albert
Little, Samantha N.
Huang, Andrew T.
Hernandez, David J.
Sandulache, Vlad C.
author_sort Soliman, Ola
collection PubMed
description OBJECTIVE: Cisplatin forms the backbone of systemic chemotherapy treatment for oropharyngeal squamous cell carcinoma (OPSCC). The ideal cisplatin dosing regimen remains yet to be fully defined for achieving optimal efficacy and toxicity profiles in patients with comorbidity. METHODS: We retrospectively reviewed oncologic and toxicity data for patients with OPSCC treated at the Michael E. DeBakey Veterans Affairs Medical Center between 2000 and 2020 who initiated curative intent, definitive chemo‐radiation with one of three single agent regimens: high dose (HD) cisplatin, low dose (LD) cisplatin or cetuximab. RESULTS: Patients with HPV‐associated tumors and nonsmokers demonstrated improved overall and disease‐free survival along with locoregional and distant metastatic control regardless of chemotherapy regimen. Regardless of regimen selection, patients which received a cumulative cisplatin dose ≥200 mg/m(2) had a lower rate of distant metastasis. The HD regimen resulted in a greater fraction (75% vs. 50%) of patients receiving a cumulative cisplatin dose ≥200 mg/m(2) and a comparable measured toxicity burden compared to the LD regimen. CONCLUSIONS: Both HD and LD cisplatin regimens can be safely delivered to a Veteran OPSCC patient population which should allow for straightforward application of conclusions drawn from completed and active clinical trials testing cisplatin regimens. LEVEL OF EVIDENCE: 4.
format Online
Article
Text
id pubmed-10446265
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-104462652023-08-24 Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes Soliman, Ola Wilde, David C. Kemnade, Jan O. Sabichi, Anita L. Chen, George Chen, Albert Little, Samantha N. Huang, Andrew T. Hernandez, David J. Sandulache, Vlad C. Laryngoscope Investig Otolaryngol Head and Neck, and Tumor Biology OBJECTIVE: Cisplatin forms the backbone of systemic chemotherapy treatment for oropharyngeal squamous cell carcinoma (OPSCC). The ideal cisplatin dosing regimen remains yet to be fully defined for achieving optimal efficacy and toxicity profiles in patients with comorbidity. METHODS: We retrospectively reviewed oncologic and toxicity data for patients with OPSCC treated at the Michael E. DeBakey Veterans Affairs Medical Center between 2000 and 2020 who initiated curative intent, definitive chemo‐radiation with one of three single agent regimens: high dose (HD) cisplatin, low dose (LD) cisplatin or cetuximab. RESULTS: Patients with HPV‐associated tumors and nonsmokers demonstrated improved overall and disease‐free survival along with locoregional and distant metastatic control regardless of chemotherapy regimen. Regardless of regimen selection, patients which received a cumulative cisplatin dose ≥200 mg/m(2) had a lower rate of distant metastasis. The HD regimen resulted in a greater fraction (75% vs. 50%) of patients receiving a cumulative cisplatin dose ≥200 mg/m(2) and a comparable measured toxicity burden compared to the LD regimen. CONCLUSIONS: Both HD and LD cisplatin regimens can be safely delivered to a Veteran OPSCC patient population which should allow for straightforward application of conclusions drawn from completed and active clinical trials testing cisplatin regimens. LEVEL OF EVIDENCE: 4. John Wiley & Sons, Inc. 2023-07-14 /pmc/articles/PMC10446265/ /pubmed/37621289 http://dx.doi.org/10.1002/lio2.1115 Text en © 2023 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Head and Neck, and Tumor Biology
Soliman, Ola
Wilde, David C.
Kemnade, Jan O.
Sabichi, Anita L.
Chen, George
Chen, Albert
Little, Samantha N.
Huang, Andrew T.
Hernandez, David J.
Sandulache, Vlad C.
Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes
title Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes
title_full Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes
title_fullStr Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes
title_full_unstemmed Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes
title_short Deployment of cisplatin in Veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes
title_sort deployment of cisplatin in veterans with oropharyngeal cancer: toxicity and impact on oncologic outcomes
topic Head and Neck, and Tumor Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10446265/
https://www.ncbi.nlm.nih.gov/pubmed/37621289
http://dx.doi.org/10.1002/lio2.1115
work_keys_str_mv AT solimanola deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT wildedavidc deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT kemnadejano deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT sabichianital deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT chengeorge deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT chenalbert deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT littlesamanthan deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT huangandrewt deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT hernandezdavidj deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes
AT sandulachevladc deploymentofcisplatininveteranswithoropharyngealcancertoxicityandimpactononcologicoutcomes